Raghav Gulati takes a one-shot lead with an impressive five-under-par 67 on Day One of the Tommy Fleetwood Pathway Series at ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

The R&A has announced the qualification pathways for The 153rd Open at Royal Portrush, taking place July 13-20, 2025. The ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

Cotargeting other parallel pathways would be justified if they are ... the nearly 3.4 million patients who receive a diagnosis of RAS-mutant cancer each year.

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

February's Full Moon, or Snow Moon, is a potent time for aligning with your deepest desires. Engaging with its energy ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will ...

Thus, we will focus primarily on the therapeutic targeting of the major RAS effector pathways, in addition to several essential co-opted pathways, as reviewed in the next section. MEK/CDK4 PD ...

Six Democratic candidates vying for New Jersey’s governorship spoke directly to voters at the first debate of the season ...

Seated L -R : H.E. Martina Strong, US Ambassador to the UAE, His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, H.E. Edward Hobart, UK Ambassador to ...